This month has become effective the creation of a new research group at Vall d'Hebron Research Institute (VHIR), the Clinical Biochemistry, Drug Delivery and Therapy group. The team was born from the union of the Clinical Biochemistry and Drug Targeting and Drug Delivery groups, previously existing at VHIR, with the objectives of improving the diagnostic and prognostic process of different diseases and developing new therapeutic strategies. Dr. Ibane Abasolo and Dr. Roser Ferrer will be the new group leaders of a team formed by more than 50 researchers.

With a direct link to the Clinical Biochemistry Service of the Vall d'Hebron University Hospital, the scope of the new group ranges from the analysis of massive data from the service, the development of diagnostic and prognostic biomarkers (for which it has a powerful chromatography-mass spectrometry platform), the evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology. The group will have as its primary affiliation the two cross-cutting and enabling eCOREs, the eCORE on Personalized Medicine, Innovative Diagnostics, Molecular Imaging and Digital Health (PerMed) and the eCORE on Advanced Therapies and Interventions, Nanomedicine, Transplantation and Donation (AVANT), where Dr. Ferrer and Dr. Abasolo are already acting as coordinators.

Regarding specific pathologies or indications, the group has extensive experience in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements to enzyme replacement therapy), renal diseases and liver diseases.